What Tesamorelin Is

Tesamorelin is a synthetic 44–amino-acid analogue of human growth hormone-releasing hormone (GHRH), structurally stabilised to resist enzymatic degradation. It is a growth hormone secretagogue — rather than introducing growth hormone directly, it prompts the pituitary to release the body’s own.

Where unmodified GHRH is cleaved within minutes by the enzyme DPP-4, tesamorelin carries an N-terminal modification that extends its stability. This lets it bind the GHRH receptor on pituitary somatotrophs and stimulate endogenous growth hormone release in the discrete, pulsatile pattern the body produces naturally — a key distinction from secretagogues that drive a sustained, continuous elevation.

For researchers in Thailand evaluating growth hormone secretagogues, tesamorelin is the reference compound — the only GHRH analogue carried through large randomised clinical trials and the molecule against which newer analogues are benchmarked. Bangkok Peptides supplies it locally, with the same purity standards and verification protocols that international researchers expect.

Tesamorelin vs Sermorelin vs CJC-1295

Tesamorelin is most often compared with sermorelin and CJC-1295 because all three are GHRH-based secretagogues that act on the same pituitary receptor. The defining distinctions are structural stability, the resulting growth hormone release pattern, and the depth of clinical evidence behind each.

Sermorelin is the original GHRH fragment analogue — biologically active but cleared so quickly that its signal is brief. CJC-1295 extended duration dramatically by binding to serum albumin, producing a sustained release that researchers describe as a continuous “GH bleed.” Tesamorelin sits between them by design: stabilised enough to be practical, but short-acting enough to trigger a discrete pulse and clear, preserving the natural pulsatile rhythm of growth hormone secretion.

That pulsatile profile is the differentiator most cited in the literature. Continuous GH elevation and physiological pulsatile release are not interchangeable in research models — the downstream signalling differs. Combined with the depth of its clinical trial record, this is what makes tesamorelin a distinct research compound rather than an incremental one.

The Research Landscape

Tesamorelin is the most extensively studied GHRH analogue in the published literature, and the only one taken through large-scale randomised controlled trials. Research models examining the compound focus on three primary themes:

Visceral adipose tissue. The most heavily studied outcome. The pivotal Phase 3 programme — Falutz and colleagues, published in the New England Journal of Medicine in 2007 — documented a 15.2% reduction in visceral adipose tissue versus a small increase under placebo across 412 subjects. Visceral fat carries higher growth hormone receptor density than subcutaneous fat, which research literature links to the compound’s tissue-selective profile.

The GH / IGF-1 axis. Because tesamorelin acts upstream on the pituitary rather than supplying growth hormone directly, much of its research profile concerns how endogenous GH release translates into IGF-1 elevation, and how that pulsatile signalling compares with continuous-elevation secretagogues.

Hepatic lipid behaviour. A substantial and growing portion of recent literature — including work by Stanley and colleagues — examines tesamorelin’s effect on liver fat, an area where its visceral-selective mechanism has drawn particular research attention.

Researchers seeking peer-reviewed primary literature can search published databases such as PubMed for current studies. The field continues to develop — review the most recent publications for current findings.

Why Source Tesamorelin Locally in Thailand

For researchers based in Thailand, sourcing tesamorelin internationally introduces three structural problems that local supply solves: customs uncertainty, freight delays, and cold-chain risk. Lyophilised peptides are stable, but they are not invulnerable — and Thailand’s climate compounds the risk profile of any package that spends weeks in transit through warehouses with inconsistent temperature control.

Bangkok Peptides operates a fully domestic supply model. Vials are stocked in Bangkok, dispatched in Bangkok, and delivered domestically across Thailand on tracked services. Researchers receive product within days rather than weeks, with provenance and handling chain that’s fully verifiable.

Delivery Across Thailand

Bangkok Peptides delivers tesamorelin nationwide via tracked courier services. Most orders qualify for same-day or next-working-day dispatch from our Bangkok facility, with delivery windows depending on destination region.

Reconstitution & Handling

Tesamorelin is supplied as a lyophilised powder in a sealed sterile vial and requires reconstitution with bacteriostatic water before research use. Standard laboratory handling procedures apply.

Reconstitute using sterile bacteriostatic water (commonly 0.9% benzyl alcohol). Inject the diluent down the inside wall of the vial rather than directly onto the lyophilised powder, then swirl gently — do not shake — until fully dissolved. The reconstituted solution should appear clear.

Store the lyophilised vial cool, dry, and protected from light prior to reconstitution. Reconstituted solutions should be refrigerated at 2–8°C, which is particularly relevant in Thailand’s climate where ambient temperatures can degrade peptide integrity rapidly. Avoid repeated freeze–thaw cycles. Lyophilised shelf life is up to 24 months when stored correctly.

Frequently Asked Questions